IL6 and congenital rubella syndrome: Cytokine release syndrome (CRS) (driven by interleukin-6 (IL-6)/IFN-γ) has occurred with brentuximab vedotin plus nivolumab, sometimes requiring IL-6 blockade [133, 134].